Cargando…

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry

Disclosure: E.B. Geer: Consulting Fee; Self; Amryt. Research Investigator; Self; Ionis, Amryt. W. Huang: Consulting Fee; Self; Amryt. Speaker; Self; Amryt. M.B. Gordon: Consulting Fee; Self; Recordati, Novo Nordisk. Research Investigator; Self; Amryt, Crinetics, Recordati, Novo Nordisk. K.C. Yuen: C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geer, Eliza Brevoort, Huang, Wenyu, Gordon, Murray B, Ji Yuen, Kevin Choong, Lubitz, Sara E, Salvatori, Roberto, Fleseriu, Maria, Ioachimescu, Adriana Gabriela, Christofides, Elena A, Sisco, Jill, Mathias, Susan D, Crompton, Jason A, Molitch, Mark E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology & Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554245/ http://dx.doi.org/10.1210/jendso/bvad114.1355

Ejemplares similares

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

SAT-472 Increased Thyroid Cancer Risk in Acromegaly: A Report of 3 Cases
por: Jaisinghani, Priya, et al.
Publicado: (2019)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

SUN-LB078 Biochemically Controlled Acromegaly Patients on a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice Still Remain Symptomatic: Preliminary Results from Endocrinology Health Care Professionals
por: Geer, Eliza, et al.
Publicado: (2019)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

SAT-267 Pregnancy in Acromegaly: Report of Five Cases
por: Burcea, Iulia Florentina, et al.
Publicado: (2020)

SAT-249 Polyarticular Osteoarthritis: A Disabling Manifestation of Acromegaly
por: Khan, Azkia, et al.
Publicado: (2020)

SAT-251 New Diagnosis of Acromegaly with DKA as Initial Presentation
por: Gundluru, Rajani, et al.
Publicado: (2020)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

SAT-LB48 Novel Genetic Variant of Carney Complex With Acromegaly
por: Cristiano, Elizabeth, et al.
Publicado: (2020)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

SAT-471 Abnormal Thyroid Function Tests in Acromegaly: A Clinical Conundrum
por: Fernandes, Stuti, et al.
Publicado: (2019)

SAT-470 A Case of Acromegaly with Concomitant Hypercortisolism Presenting with Diabetic Ketoacidosis
por: Gonzales, Irish Judy
Publicado: (2019)

MON-321 AgRP and Food Cravings Decrease with Treatment of Cushing’s Disease
por: Haseltine, Katherine N, et al.
Publicado: (2020)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

SAT-LB078 Acromegaly Disease Activity According to ACRODAT® in Spain: ACROVAL Study
por: Marazuela, Monica, et al.
Publicado: (2019)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
por: Fleseriu, Maria, et al.
Publicado: (2022)

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

SAT-436 Adjuvant Therapeutic Modalities in Acromegaly: Clinical Course and Factors Predicting Biochemical Controls
por: Jung, Hyein, et al.
Publicado: (2019)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

SUN-LB074 Racial Distribution, Presentation and Outcome in Acromegaly and Cushing's Disease: A Tertiary Referral Center Study in 220 Patients
por: Goswami, Neevedita, et al.
Publicado: (2019)

SAT-469 Empty Sella Making Big Changes: A Case of Acromegaly and Empty Sella Syndrome
por: Padniewski, Jessica, et al.
Publicado: (2019)

SAT-466 Cases of Acromegaly and Presumed Prolactinoma in Setting of Empty Sella Syndrome: Presentation and Management Implications
por: Uwaifo, Gabriel
Publicado: (2019)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

SAT-259 Acromegaly by Pituitary Adenoma Associated with ACTH-Independent Cushing Syndrome by Adrenal Carcinoma: Case Report
por: Minuzzi, Ricardo Kunde, et al.
Publicado: (2020)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SAT-431 Parameters of Glucose Metabolism Independently Predict Post Glucose Load Growth Hormone Concentrations in Patients with Acromegaly
por: Micko, Alexander, et al.
Publicado: (2019)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m0rkktprv0r60thobr918rmmmn